Several studies have reported an association of levels of lipoprotein(a) (Lp[a]) and the content of oxidized phospholipids on apolipoprotein B (OxPL-apoB) and apolipoprotein(a) (OxPL-apo[a]) with faster calcific aortic valve stenosis (CAVS) progression. However, whether this association is threshold or linear remains unclear.
C alcific aortic valve stenosis (CAVS) is the most common valvular heart disease. 1 At present, no medical treatment is available for these patients, and the only remaining option is to perform an aortic valve replacement. 2 Single-nucleotide polymorphisms in the LPA gene have been identified as the only genome-wide significant singlenucleotide polymorphisms to be associated with CAVS. [3] [4] [5] Furthermore, plasma levels of lipoprotein(a) (Lp[a] ) and its associated content in oxidized phospholipids on apolipoprotein B (OxPL-apoB) and apolipoprotein(a) (OxPL-apo[a] ) are indicative of hemodynamic progression of CAVS and higher risk of aortic valve replacement. 6 The role of OxPL in aortic valve disease has recently been corroborated by the comprehensive analysis of a transgenic mouse model, where overexpression of the antibody E06 resulted in reduced aortic valve calcification and reduced peak gradient. 7 However, whether this association is threshold or linear remains unclear. Using data from the ASTRONOMER (Effects of Rosuvastatin on Aortic Stenosis Progression) trial, we tested the hypothesis that Lp(a), OxPLapoB, and OxPL-apo(a) plasma levels were linearly associated with a faster rate of CAVS progression.
Methods

Patient Population
The design and main results of the ASTRONOMER trial have been previously reported. 8 The ASTRONOMER trial included adults (age range, 18-82 years) with mild to moderate aortic stenosis at baseline (peak aortic jet velocity [V peak ], 2.5-4.0 m/s) recruited in 23 Canadian sites from January 1, 2002 , through December 31, 2005 . Exclusion criteria were severe or symptomatic AS, severe aortic regurgitation, significant mitral valve disease (ie, mitral stenosis or regurgitation), symptomatic coronary artery disease, congestive heart failure, diabetes, or the need for treatment to lower low-density lipoprotein cholesterol levels. Patients were randomized to rosuvastatin calcium, 40 mg, vs placebo. The study protocol was approved by the institutional review boards at all participating centers, and patients gave written informed consent.
Clinical, Laboratory, and Doppler Echocardiographic Data
Clinical, laboratory, and Doppler echocardiographic data for the ASTRONOMER trial have been described previously (eMethods in the Supplement). 6, 9 Briefly, clinical data included age, sex, anthropometric data, and comorbidities. In a fasting sample of plasma collected at baseline and stored at −80°C, levels of OxPL-apoB, OxPL-apo(a), and Lp(a) were subsequently measured in a subset of 220 patients from the ASTRONOMER trial in an ad hoc secondary analysis. The main Doppler echocardiographic index used to assess CAVS severity was V peak .
Study Outcome
The outcome variable was the progression rate of valve stenosis measured as annualized changes in V peak . To account for different follow-up lengths, annualized changes in V peak were calculated by dividing the difference between last follow-up and baseline values by the length of follow-up.
Statistical Analysis
Data were analyzed from April 1 through September 1, 2018. Continuous data were expressed as mean (SD). One-way analysis of variance, followed by a post hoc Tukey test, was used to compare the progression rate of CAVS across patient groups with increasing plasma levels of Lp(a), including the reference group (as previously published 6 ) with Lp(a) levels of less than 60 mg/dL (n = 149) vs the group with Lp(a) levels of 60 to 100 mg/dL (group 1 [n = 43] ) and the group with Lp(a) levels of greater than 100 mg/dL (group 2 [n = 28]) (to approximate Lp[a] levels to nanomoles per liter, multiply by 2.5). The cutoff values used to determine groups for OxPL-apoB and OxPL-apo(a) levels were defined to have the same number of patients in each group (ie, 149 in the reference group, 43 in group 1, and 28 in group 2). Cutoffs then used included 5.8 and 13.0 nM for OxPL-apoB and 36.0 and 72.0 nM for OxPL-apo (a). Univariable and multivariable linear regression analyses were performed to identify the independent indicators of CAVS progression as annualized progression rates of peak aortic jet velocity. Baseline plasma levels of Lp(a), OxPL-apoB, and OxPLapo(a) were entered in these models in continuous format. As previously described, 6 the multivariable model included the following variables: (1) variables with P < .10 in individual analysis (ie, metabolic syndrome, systolic blood pressure, apoB level, creatinine level, baseline aortic valve calcification score, baseline peak aortic jet velocity, and valvuloarterial impedance), [SE] ). Univariable and multivariable logistic regression models were also performed to identify the risk of rapid progress, defined as an annualized progression rate of V peak of at least 0.20 m/s per year as previously described. 6 Results were reported as odds ratios (ORs) with 95%
Key Points
Question Is the association of increased lipoprotein(a) and oxidized phospholipid levels with a faster rate of calcific aortic valve stenosis progression a linear or a threshold association?
Findings In a secondary analysis of the ASTRONOMER trial following up a cohort of 220 patients with mild to moderate aortic stenosis, a significant linear association was found between plasma levels of lipoprotein(a) and oxidized phospholipids on apolipoprotein B and apolipoprotein(a) and a faster rate of aortic stenosis progression.
Meanings By documenting the linear association of lipoprotein(a) and its content of oxidized phospholipids with faster progression of calcific aortic stenosis, this study has pathophysiological and clinical implications for these patients.
CIs. Levels of Lp(a), OxPL-apoB, and OxPL-apo(a) were not included in the same model owing to their strong correlation (r > 0.85 for all), resulting in a high level of multicollinearity (ie, variance inflation factor >5). Two-tailed P < .05 was considered statistically significant.
Results
Baseline clinical, laboratory, and Doppler echocardiographic characteristics of the studied population were previously reported. 6 We reported the main characteristics in , 4.5-51.7 nM) . At baseline, the mean peak aortic jet velocity was 3.2 (0.4) m/s, and 105 (47.7%) had a bicuspid aortic valve. The median follow-up was 3.5 years (IQR, 2.9-4.5 years). There was no difference in clinical and Doppler echocardiographic data, and especially regarding the baseline severity of aortic stenosis, across the 3 groups of Lp(a) plasma levels ( Table 1) . As expected, the only laboratory markers that reached significance levels were corrected levels of low- (17) 128 (18) 127 (14) 121 (15) . 17 Diastolic 75 (10) 76 (10) 74 (10) 73 (11 (60) 122 (61) 123 (64) 102 (47) . 28 Fasting glucose level, mean (SD), mg/dL 95 (11) 95 (12) 94 (9) 93 (9) .52
Creatinine Peak aortic jet velocity, mean (SD), m/s
Transvalvular gradient, mean (SD), mm Hg 22 (7) 23 (7) 22 (7) 21 (7 Plasma levels of Lp(a) (β coefficient, 0.18; SE, 0.001; P = .006), OxPL-apoB (β coefficient, 0.21; SE, 0.003; P = .002), and OxPL-apo(a) (β coefficient, 0.20; SE, 0.001; P = .003) were significantly associated with faster CAVS progression rate ( Table 2) . After comprehensive multivariable adjustment, plasma levels of Lp(a) (β coefficient, 0.26; SE, 0.004; P = .003), OxPL-apoB (β coefficient, 0.28; SE, 0.003; P = .001), and OxPL-apo(a) (β coefficient, 0.25; SE, 0.001; P = .005) were independently associated with CAVS progression rate ( Table 2 ). The use of logarithm transformation of Lp(a), OxPL-apoB, or OxPL-apo(a) levels instead of their absolute values provided consistent results (eTable in the Supplement). In the subset of 108 patients 57 years or younger (ie, median age for the cohort), the association between CAVS progression rate and Lp(a), OxPL-apoB, and OxPL-apo(a) levels in continuous format was also significant in univariable and after comprehensive multivariable adjustment (β coefficient, ≥ 0.43; SE, ≤ 0.004; P ≤ .01 for all) ( Table 2 and eTable in the Supplement). When we analyzed the risk of rapid progress, defined as annualized V peak of greater than 0.20 m/s per year, there was a significant association for levels of Lp(a) (OR per 10-mg/dL increase, 1.10; 95% CI, 1.03-1.19; P = .006), OxPLapoB (OR per 1-nM increase, 1.06; 95% CI, 1.01-1.12; P = .02), and OxPL-apo(a) (OR per 10-nM increase, 1.16; 95% CI, 1.05-1.27; P = .002). The association remained significant after multivariable adjustment for levels of Lp(a) (OR per 10-mg/dL increase, 1.28; 95% CI, 1.10-1.48; P = .001), OxPL-apoB (OR per 1-nM increase, 1.13; 95% CI, 1.03-1.25; P = .007), and OxPLapo(a) (OR per 10-nM increase, 1.41; 95% CI, 1.16-1.73; P = .002) ( Table 2 ). Similar to the previous analysis, the analysis of Lp(a), OxPL-apoB, and OxPL-apo(a) levels after logarithm transformation (eTable in the Supplement) or in the subset of younger patients (ie, ≤57 years old) ( Table 2 ) provided consistent results.
Discussion
This study documents that in patients with preexisting mild to moderate CAVS, the association of Lp(a), OxPL-apoB, and OxPL-apo(a) with more rapid progression of CAVS is linear, as measured by continually increasing V peak . These data add to the increasing database that Lp(a) is not only associated with prevalent aortic valve calcification, but also with rapid progression of preexisting CAVS. These data are clinically relevant in the care of these patients, in that rapid progression may be identified easily with a plasma biomarker that may be causal in the pathway of the development and progression of CAVS. Furthermore, the parallel association of OxPL-apoB and OxPL-apo(a), biomarkers that primarily reflect the OxPL content on Lp(a), suggests that the OxPL carried by Lp(a) may be responsible for the proinflammatory and procalcifying effects of Lp(a) in CAVS. [10] [11] [12] [13] This study has pathophysiological and clinical implications in the surveillance of patients with mild to moderate CAVS. First, it supports the causality of Lp(a) and OxPL in CAVS 7 and documents a linear association with progression of preexisting CAVS. Second, it identifies a group of patients with an exceedingly high progression rate, at approximately 0.30 to 0.35 m/s per year, who would need more frequent surveillance of progression. Third, it supports the measurement of at least 1 Lp(a) level in patients with CAVS. With the high prevalence (approximately 35%) of elevated Lp(a) levels (>30 mg/dL) 14 and the development of potent therapies to lower Lp(a) levels 15 and methods to inactivate OxPL, 7 these findings may influence the design of future intervention trials in patients with CAVS.
Limitations
Study limitations include that these patients were relatively young and had mild to moderate AS. Whether these findings apply to older patients with severe AS remains to be determined.
Conclusions
In patients with preexisting CAVS, the levels of Lp(a), OxPLapoB, and OxPL-apo(a) may allow estimation of the rate of progression that can be expected. These data need to be valid a t e di nl a r g e rd a t as e t st od e f i n et h ep o t e n t i a lr o l eo f surveillance in clinical care. Author Contributions: Drs Pibarot and Tsimikas had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Role of the Funder/Sponsor: The funders/ sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. 
ARTICLE INFORMATION
Doppler echocardiographic data
Randomly selected studies that contributed 10% of the total number of echocardiograms were reviewed to ensure that the studies and measurements were performed in accordance with the protocol. we calculated the valvulo-arterial impedance (5): Zva=(SBP+ Pmean)/SVi where SBP is the systolic blood pressure, ∆Pmean the mean transvalvular gradient, and SVi is the stroke volume indexed to a 2.04 power of height (4) .
Laboratory data
The plasma levels of glucose, creatinine, total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides, and apolipoprotein B (apoB) were measured in fasting plasma samples using standardized techniques. LDL-C was corrected for the cholesterol content in Lp(a) using the following formula: corrected LDL-C = LDL-C -Lp(a) mass in mg/dl × 0.3. 1, 2 Using frozen plasma sample stored at -80°C, levels of OxPL -apoB-100, OxPLapo(a) were measured with chemiluminescent ELISAs, as previously described in a subset of 220 patients from the ASTRONOMER trial (82% of the cohort). 3 Lp(a) was measured with a validated ELISA as previously described. 4, 5 eTable. Log Lp(a) 1.31 (1.00-1.72) .047 1.39 (1.02-1.88) .04 1.97 (1.27-3.08) .003 2.53 (1.39-4.61) .002
Log OxPL-apoB 1.35 (0.97-1.88) .08 1.54 (1.06-2.24) .03 1.98 (1.18-3.32) .009 2.80 (1.39-5.65) .004
Log OxPL-apo(a) 1.21 (0.99-1.49) .06 1.26 (1.00-1.59) .046 1.67 (1.20-2.34) .003 2.05 (1.29-3.25) .002
CAVS: calcific aortic valve stenosis; Log: logarithmic transformation; Lp(a): lipoprotein(a); OxPL: oxidized phospholipids; apoB: apolipoprotein B; apo(a): apolipoprotein (a); CAVS progression rate is defined by the annualized progression of peak aortic jet velocity; eta coeff. is the standardized raw-score regression coefficient ±SE from the linear regression
